ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD depression trial results expected early August
|
|
Stungun
|
107 |
54K |
7 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
107
|
54K
|
7
|
|
ASX - By Stock
|
ACW |
Re:
EU regulators reject Leqembi for Alzheimers
|
|
Stungun
|
26 |
10K |
5 |
30/07/24 |
30/07/24 |
ASX - By Stock
|
26
|
10K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD depression trial results expected early August
|
|
Stungun
|
107 |
54K |
9 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
107
|
54K
|
9
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Positive Xanamem biomarker trial published in Jnl Alz Dis
|
|
Stungun
|
88 |
34K |
2 |
29/06/24 |
29/06/24 |
ASX - By Stock
|
88
|
34K
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
|
|
Stungun
|
506 |
236K |
13 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
506
|
236K
|
13
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm
|
|
Stungun
|
147 |
70K |
30 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
147
|
70K
|
30
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen awarded UK Innovation Passport for Xanamem
|
|
Stungun
|
73 |
20K |
3 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
73
|
20K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen awarded UK Innovation Passport for Xanamem
|
|
Stungun
|
73 |
20K |
1 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
73
|
20K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen awarded UK Innovation Passport for Xanamem
|
|
Stungun
|
73 |
20K |
1 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
73
|
20K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Application for quotation of securities - ACW
|
|
Stungun
|
25 |
8.0K |
0 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
25
|
8.0K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen awarded UK Innovation Passport for Xanamem
|
|
Stungun
|
73 |
20K |
4 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
73
|
20K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW December 2023 quarterly activity report & Appendix 4C
|
|
Stungun
|
17 |
5.4K |
5 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
17
|
5.4K
|
5
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW December 2023 quarterly activity report & Appendix 4C
|
|
Stungun
|
17 |
5.4K |
1 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
17
|
5.4K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Positive Xanamem brain PET study peer-reviewed publication
|
|
Stungun
|
39 |
13K |
8 |
24/01/24 |
24/01/24 |
ASX - By Stock
|
39
|
13K
|
8
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Stungun
|
27K |
13M |
9 |
12/01/24 |
12/01/24 |
ASX - By Stock
|
27K
|
13M
|
9
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Stungun
|
27K |
13M |
2 |
12/01/24 |
12/01/24 |
ASX - By Stock
|
27K
|
13M
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Stungun
|
27K |
13M |
32 |
30/12/23 |
30/12/23 |
ASX - By Stock
|
27K
|
13M
|
32
|
|
ASX - By Stock
|
ACW |
Re:
Ann: First site activated in ACW XanaMIA Phase 2b AD trial
|
|
Stungun
|
12 |
7.3K |
8 |
25/12/23 |
25/12/23 |
ASX - By Stock
|
12
|
7.3K
|
8
|
|
ASX - By Stock
|
ACW |
Re:
Ann: First site activated in ACW XanaMIA Phase 2b AD trial
|
|
Stungun
|
12 |
7.3K |
5 |
21/12/23 |
21/12/23 |
ASX - By Stock
|
12
|
7.3K
|
5
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Stungun
|
27K |
13M |
24 |
17/12/23 |
17/12/23 |
ASX - By Stock
|
27K
|
13M
|
24
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Stungun
|
16K |
7.7M |
27 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
16K
|
7.7M
|
27
|
|
ASX - By Stock
|
IMU |
Re:
Ann: FDA Fast Track Designation Granted for VAXINIA Trial Program
|
|
Stungun
|
412 |
180K |
3 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
412
|
180K
|
3
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Stungun
|
16K |
7.7M |
11 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
16K
|
7.7M
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Stungun
|
27K |
13M |
7 |
18/11/23 |
18/11/23 |
ASX - By Stock
|
27K
|
13M
|
7
|
|
ASX - By Stock
|
IMU |
Re:
Check-vacc - possible complete response case study!
|
|
Stungun
|
78 |
36K |
19 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
78
|
36K
|
19
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Investor Webinar - MAST Study Update
|
|
Stungun
|
228 |
98K |
20 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
228
|
98K
|
20
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Stungun
|
16K |
7.7M |
11 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
16K
|
7.7M
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 CF33 VAXINIA Study Update - Positive Early Signals
|
|
Stungun
|
315 |
152K |
18 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
315
|
152K
|
18
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW CEO presents to Dementia Trials Australia conference
|
|
Stungun
|
6 |
2.9K |
3 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
6
|
2.9K
|
3
|
|
ASX - By Stock
|
IMU |
Re:
Can they run a business?
|
|
Stungun
|
155 |
55K |
1 |
12/09/23 |
12/09/23 |
ASX - By Stock
|
155
|
55K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Stungun
|
27K |
13M |
9 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
27K
|
13M
|
9
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Actinogen closes successful $10 million rights issue offer
|
|
Stungun
|
33 |
13K |
3 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
33
|
13K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Green light
|
|
Stungun
|
8 |
2.6K |
1 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
8
|
2.6K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Green light
|
|
Stungun
|
8 |
2.6K |
0 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
8
|
2.6K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Green light
|
|
Stungun
|
8 |
2.6K |
0 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
8
|
2.6K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Investor Webinar on Acquisition of License for Azer-cel
|
|
Stungun
|
335 |
125K |
0 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
335
|
125K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
|
|
Stungun
|
506 |
236K |
10 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
506
|
236K
|
10
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
|
|
Stungun
|
506 |
236K |
3 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
506
|
236K
|
3
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
|
|
Stungun
|
506 |
236K |
12 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
506
|
236K
|
12
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy
|
|
Stungun
|
107 |
57K |
31 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
107
|
57K
|
31
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy
|
|
Stungun
|
107 |
57K |
16 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
107
|
57K
|
16
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Stungun
|
27K |
13M |
7 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
27K
|
13M
|
7
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Stungun
|
27K |
13M |
31 |
06/08/23 |
06/08/23 |
ASX - By Stock
|
27K
|
13M
|
31
|
|
ASX - By Stock
|
IMU |
Re:
City of Hope cancer treatment
|
|
Stungun
|
47 |
25K |
12 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
47
|
25K
|
12
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Stungun
|
27K |
13M |
92 |
30/07/23 |
30/07/23 |
ASX - By Stock
|
27K
|
13M
|
92
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW CEO presents at Bioshares Biotech Summit
|
|
Stungun
|
9 |
3.0K |
0 |
29/07/23 |
29/07/23 |
ASX - By Stock
|
9
|
3.0K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW CEO presents at Bioshares Biotech Summit
|
|
Stungun
|
9 |
3.0K |
0 |
29/07/23 |
29/07/23 |
ASX - By Stock
|
9
|
3.0K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO
|
|
Stungun
|
155 |
80K |
25 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
155
|
80K
|
25
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Corporate Presentation
|
|
Stungun
|
246 |
118K |
25 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
246
|
118K
|
25
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene Corporate Presentation
|
|
Stungun
|
246 |
118K |
10 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
246
|
118K
|
10
|
|